6495

Cipla’s new malaria drug gets WHO nod

This combination drug is currently marketed by Cipla in India under the brand name Mefliam Plus
Comment E-mail Print Share
First Published: Wed, Oct 03 2012. 09 08 PM IST
Cipla can supply the new malaria drug to other markets under WHO’s anti-malaria programmes and also independently.
Cipla can supply the new malaria drug to other markets under WHO’s anti-malaria programmes and also independently.
Updated: Wed, Oct 03 2012. 09 30 PM IST
Mumbai: The country’s third largest drug maker by sales Cipla Ltd. and Drugs for Neglected Diseases Initiative or DNDi, a not for profit research and development organization, have said on Wednesday that the new malaria drug, a fixed dose combination of artesunate and mefloquine developed by them has been pre-qualified or recommended by the World Health Organization (WHO). This combination drug is currently marketed by Cipla in India under the brand name Mefliam Plus, and by the WHO pre-qualification it can supply this drug to other markets under the WHO’s anti-malaria programmes and also independently.
“The prequalification announcement is a recognition that Mefliam Plus meets WHO’s high quality standards and we aim to make this treatment widely available throughout Asia’, said Jaideep Gogtay, medical director, Cipla.
“The availability of this fixed dose combination will have a direct impact on patients, especially in Asia’, said Bernard Pécoul, executive director, DNDi. ‘It addresses an important public health need in the region as it forms part of the malaria treatment arsenal necessary to control the disease.’
Local drug maker Ranbaxy Laboratories Ltd. had also developed a similar combination drug for the treatment of Malaria in collaboration with the government of India.
Comment E-mail Print Share
First Published: Wed, Oct 03 2012. 09 08 PM IST
More Topics: Cipla | Malaria | Drug | Mefliam Plus | WHO |
blog comments powered by Disqus
  • Wed, Apr 16 2014. 06 11 PM
  • Wed, Apr 09 2014. 05 19 PM
ALSO READ close

Ranbaxy’s woes add $900 million in costs for heart drug

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved